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Sir,
We thank the correspondent for his interest in our report.
Dr Tirelli has raised important questions regarding the specific
subgroup of urological cancer patients included in our previous
reported series (Arkenau et al, 2008).
Dr Tirelli made the point that 66% of the castration-resistant
prostate cancer (CRPC) patients included in the analysis were
chemotherapy-naive. In 2004, two phase-III studies (Tannock et al,
2004; Petrylak et al, 2004) demonstrated an overall survival (OS)
benefit approximating a median of 2.5 months for chemotherapy-
naive CRPC patients who received docetaxel-based treatment
compared to mitoxantrone/prednisone. This led to the approval of
this agent in the setting of CRPC in the United Kingdom in
June 2006. These circumstances explain why 37 of the 54 CRPC
patients included in our analysis were chemotherapy-naive.
All the remaining 17 patients received chemotherapy before
their phase-I entry (including 10 patients who received prior
docetaxel).
The superior outcome of the urological cancer patients sub-
group in comparison with the non-urological tumour patients in
our series could be attributed to the use of active agents in the
former group. In fact, a high proportion of CRPC patients were
treated in taxane combination phase-I trials (27 of 37 chemo-naive
patients). Furthermore, many patients received abiraterone
acetate, a novel CYP17-specific inhibitor, within this analysis or
later; this agent has already shown preliminary promising activity
(Attard et al, 2008). In addition, our urological cancer patients
cohort include bladder and renal cancer patients, and many of
them were treated within taxane combinations or novel antiangio-
genic phase-I trials, respectively.
Although additional retrospective CRPC subgroups analysis
comparing outcomes in chemo-pretreated and chemo-naive
patients would be interesting, we note that the numbers in each
of these groups are small (ie, 17 and 37, respectively) and the
results from such analysis have to be treated with extreme caution.
Prospective, randomised trials would be necessary to address the
question of the optimal timing of docetaxel administration, and
therefore the best timing for phase-I consideration relative to
conventional chemotherapy in CRPC.
Nonetheless, overall, these retrospective data provide prelimin-
ary clinical and ethical support for the exploration of novel agents
both before and after docetaxel within early clinical trials,
especially in CRPC patients where advances over the last two
decades have been small.
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